Posted by Michael Wonder on 19 Jul 2026
US FDA accepts BioMarin’s supplemental new drug application for full approval of Voxzogo (vosoritide) for children with achondroplasia
13 July 2026 - BioMarin today announced that the US FDA has accepted the company's supplemental new drug application for Voxzogo (vosoritide) for full approval in children with achondroplasia.
The FDA has set a PDUFA target action date of 28 February 2027.
